These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8649058)

  • 1. Hodgkin's disease: from basic science to clinical application.
    Tesch H; Diehl V
    Leukemia; 1996 Jun; 10 Suppl 2():s74-7. PubMed ID: 8649058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogenesis and therapy of Hodgkin lymphoma].
    Tesch H; Bohlen H; Wolf J; Engert A
    Med Klin (Munich); 1998 Feb; 93(2):82-90. PubMed ID: 9545706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hodgkin disease--pathogenesis and therapy].
    Wolf J; Diehl V
    Ther Umsch; 1996 Feb; 53(2):140-6. PubMed ID: 8629264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander.
    Oudejans JJ; Jiwa NM; Meijer CJ
    J Pathol; 1997 Apr; 181(4):353-6. PubMed ID: 9196428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
    Williams SF; Bitran JD
    Hematol Oncol Clin North Am; 1989 Jun; 3(2):319-30. PubMed ID: 2663830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress and controversy in treatment of Hodgkin's disease].
    Robak T
    Acta Haematol Pol; 1995; 26(4):343-52. PubMed ID: 8571735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Hodgkin's disease.
    Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
    Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Laport GF; Williams SF
    Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical Hodgkin and Reed-Sternberg cells demonstrate a non-clonal immature B lymphoid lineage: evidence from a single cell assay and in situ hybridization.
    Ohshima K; Suzumiya J; Mukai Y; Tashiro K; Shibata T; Tanaka T; Kato A; Kikuchi M
    Hematol Oncol; 1996 Sep; 14(3):123-36. PubMed ID: 9119357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and in situ hybridization.
    Valente G; Secchiero P; Lusso P; Abete MC; Jemma C; Reato G; Kerim S; Gallo RC; Palestro G
    Am J Pathol; 1996 Nov; 149(5):1501-10. PubMed ID: 8909240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.